Sector ratings NovoCure Limited

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 18/09/2024 BST			5-day change	1st Jan Change
17.61 ^USD	-2.28%		+2.21%	+17.95%

09-03	NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor	MT
09-03	Novocure Announces CEO Changes, Effective January 1, 2025	CI

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Composite Visibility	ESG Refinitiv	Capi. ($)
NOVOCURE LIMITED	-		C-	1.95B
PENUMBRA, INC.			C+	7.27B
MASIMO CORPORATION	-		C-	6.15B
GETINGE AB			B	6.05B
ASAHI INTECC CO., LTD.			B-	4.98B
APT MEDICAL INC.			-	4.45B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.			D+	4.35B
INARI MEDICAL, INC.	-		C	2.57B
SKAN GROUP AG			-	2.13B
SHENZHEN YHLO BIOTECH CO., LTD.	-		-	1.71B
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD		-	-	1.22B
IMPLANTICA AG	-	-	-	1.19B
CHEMOMETEC A/S			D	1.11B
BIOVENTUS INC.			C	741M
SI-BONE, INC.	-		B-	654M
SHANGHAI SANYOU MEDICAL CO., LTD	-	-	-	630M
WON TECH CO.,LTD.			-	469M
ZIMVIE INC.	-		-	466M
Average			C	2.67B
Weighted average by Cap.			C